PL1687066T3 - Sposoby modulowania odporności - Google Patents
Sposoby modulowania odpornościInfo
- Publication number
- PL1687066T3 PL1687066T3 PL04810895T PL04810895T PL1687066T3 PL 1687066 T3 PL1687066 T3 PL 1687066T3 PL 04810895 T PL04810895 T PL 04810895T PL 04810895 T PL04810895 T PL 04810895T PL 1687066 T3 PL1687066 T3 PL 1687066T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- modulating immunity
- immunity
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52014803P | 2003-11-14 | 2003-11-14 | |
US56774104P | 2004-05-03 | 2004-05-03 | |
EP04810895A EP1687066B1 (en) | 2003-11-14 | 2004-11-12 | Methods of modulating immunity |
PCT/US2004/037910 WO2005048935A2 (en) | 2003-11-14 | 2004-11-12 | Methods of modulating immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1687066T3 true PL1687066T3 (pl) | 2013-01-31 |
Family
ID=34623123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04810895T PL1687066T3 (pl) | 2003-11-14 | 2004-11-12 | Sposoby modulowania odporności |
Country Status (10)
Country | Link |
---|---|
US (3) | US7883703B2 (pl) |
EP (2) | EP1687066B1 (pl) |
JP (1) | JP5027512B2 (pl) |
AU (1) | AU2004291107B2 (pl) |
CA (1) | CA2545806C (pl) |
DK (1) | DK1687066T3 (pl) |
ES (1) | ES2393674T3 (pl) |
HK (1) | HK1098085A1 (pl) |
PL (1) | PL1687066T3 (pl) |
WO (1) | WO2005048935A2 (pl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
CA2545806C (en) | 2003-11-14 | 2014-09-16 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
AU2005250499B2 (en) | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
SG177944A1 (en) * | 2005-07-11 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
EP2023955A4 (en) * | 2006-06-06 | 2009-10-28 | Tolerrx Inc | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
WO2007147090A2 (en) * | 2006-06-14 | 2007-12-21 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
US8877198B2 (en) * | 2006-10-26 | 2014-11-04 | Wisconsin Alumni Research Foundation | Methods of reducing phosphate absorption |
CA2667802A1 (en) * | 2006-11-03 | 2008-05-29 | Northwestern University | Multiple sclerosis therapy |
AU2007337082A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics Inc. | Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
US20090131329A1 (en) * | 2007-09-14 | 2009-05-21 | Edmund John Miller | Treatment for allograft rejection |
CA2712404A1 (en) * | 2008-01-18 | 2009-07-23 | Hadasit Medical Research Services & Development Ltd. | Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
EP3231816A1 (en) | 2008-03-13 | 2017-10-18 | Immuron Limited | Bovine colostrum comprising anti-insulin antibodies for treating diabetes, non alcoholic fatty liver disease, hyperlipidemia or atherosclerosis. |
WO2011097477A1 (en) * | 2010-02-04 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
JP2013525420A (ja) * | 2010-04-29 | 2013-06-20 | ナスバックス リミテッド | 抗cd3免疫分子療法により肝炎を治療する方法および組成物 |
JP6141831B2 (ja) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | ヒト及び非ヒトcd3に結合可能なcd3結合分子 |
ES2690557T3 (es) | 2011-06-02 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Nanopartículas conjugadas a un agente antinucleolina |
ES2893855T3 (es) * | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
JP2015091761A (ja) * | 2012-02-23 | 2015-05-14 | 国立大学法人大阪大学 | 中枢神経の損傷を治療するための組成物およびその利用 |
US20150132289A1 (en) * | 2012-02-29 | 2015-05-14 | Therapix Biosciences Ltd. | Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy |
US10000567B2 (en) | 2012-06-14 | 2018-06-19 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (CD3) |
KR101941004B1 (ko) * | 2013-03-25 | 2019-01-23 | 주식회사 엘지화학 | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 |
US10857237B2 (en) | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
JOP20200303A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
DE102018213030A1 (de) | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
MA55717A (fr) | 2019-04-19 | 2022-02-23 | Janssen Biotech Inc | Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3 |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
CA3185105A1 (en) * | 2020-07-30 | 2022-02-03 | Kunwar Shailubhai | Cd-3 antibodies for the treatment of coronavirus |
WO2022162518A2 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
WO2022221767A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4654210A (en) | 1979-04-26 | 1987-03-31 | Ortho Pharmaceutical Corporation | Methods and compositions using complement fixing monoclonal antibody to human T cells |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
CA1339256C (en) | 1989-01-26 | 1997-08-12 | Wulf Droge | Treatment of diseases associated with hiv-infections |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
JP2546544B2 (ja) | 1989-10-27 | 1996-10-23 | アーチ ディベラップメント コーポレイション | 免疫強化を促進するための方法と組成物 |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
ATE237638T1 (de) | 1991-07-25 | 2003-05-15 | Idec Pharma Corp | Rekombinante antikörper zur humanen therapie |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5556763A (en) | 1992-04-06 | 1996-09-17 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Evaluation and treatment of patients with progressive immunosuppression |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
AU6983594A (en) * | 1993-06-28 | 1995-01-17 | Lion Corporation | Composition for oral cavity |
US6090380A (en) | 1994-01-12 | 2000-07-18 | Research Corporation Technologies, Inc. | Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
WO1998014209A1 (en) * | 1996-10-02 | 1998-04-09 | Ovimmune, Inc. | Oral administration of chicken yolk antibodies to treat disease |
WO1998047531A2 (en) * | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US7041289B1 (en) * | 1997-12-05 | 2006-05-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for treating established spontaneous auto-immune diseases in mammals |
WO2000062806A1 (en) * | 1999-04-19 | 2000-10-26 | Richard Weisbart | Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
US6197328B1 (en) | 1999-08-20 | 2001-03-06 | Dott Research Laboratory | Nasally administrable compositions |
US6346247B1 (en) * | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
AUPQ431299A0 (en) * | 1999-11-26 | 1999-12-23 | Unisearch Limited | Method of inducing immune tolerance |
GB0001710D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
AU6604701A (en) | 2000-06-07 | 2001-12-17 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method to induce the TH1 immune response |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
WO2003009812A2 (en) | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
GB2380127A (en) * | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
WO2003041777A1 (en) * | 2001-11-14 | 2003-05-22 | Nektar Therapeutics | Aerosolization device with improved endpiece connection |
JP2005517025A (ja) * | 2002-02-08 | 2005-06-09 | エクサイト セラピーズ, インコーポレイテッド | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
WO2003068934A2 (en) * | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
WO2003077834A2 (en) * | 2002-03-15 | 2003-09-25 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
EP1567192A4 (en) * | 2002-12-05 | 2006-02-08 | Protein Design Labs Inc | TECHNIQUES FOR TREATING ULCERO-HEMORRHAGIC RECTO-COLITIS WITH ANTI-CD3 ANTIBODIES |
US20050042664A1 (en) * | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
CA2545806C (en) | 2003-11-14 | 2014-09-16 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
IL172175A0 (en) | 2005-11-24 | 2011-08-01 | Hadasit Med Res Service | Beta glycolipids as immuno-modulators |
CA2712404A1 (en) | 2008-01-18 | 2009-07-23 | Hadasit Medical Research Services & Development Ltd. | Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
-
2004
- 2004-11-12 CA CA2545806A patent/CA2545806C/en not_active Expired - Fee Related
- 2004-11-12 AU AU2004291107A patent/AU2004291107B2/en not_active Ceased
- 2004-11-12 EP EP04810895A patent/EP1687066B1/en not_active Not-in-force
- 2004-11-12 ES ES04810895T patent/ES2393674T3/es active Active
- 2004-11-12 EP EP11162260.1A patent/EP2397189B1/en not_active Not-in-force
- 2004-11-12 PL PL04810895T patent/PL1687066T3/pl unknown
- 2004-11-12 JP JP2006539927A patent/JP5027512B2/ja not_active Expired - Fee Related
- 2004-11-12 DK DK04810895.5T patent/DK1687066T3/da active
- 2004-11-12 US US10/987,380 patent/US7883703B2/en active Active
- 2004-11-12 WO PCT/US2004/037910 patent/WO2005048935A2/en active Application Filing
-
2007
- 2007-02-07 HK HK07101418.5A patent/HK1098085A1/xx not_active IP Right Cessation
-
2010
- 2010-12-30 US US12/982,390 patent/US20110165177A1/en not_active Abandoned
-
2014
- 2014-11-07 US US14/535,693 patent/US9850305B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2005048935A2 (en) | 2005-06-02 |
ES2393674T3 (es) | 2012-12-27 |
US20050196395A1 (en) | 2005-09-08 |
EP2397189B1 (en) | 2015-03-18 |
US7883703B2 (en) | 2011-02-08 |
JP5027512B2 (ja) | 2012-09-19 |
EP1687066A4 (en) | 2008-09-24 |
DK1687066T3 (da) | 2012-11-26 |
EP1687066A2 (en) | 2006-08-09 |
CA2545806A1 (en) | 2005-06-02 |
HK1098085A1 (en) | 2007-07-13 |
US20150064197A1 (en) | 2015-03-05 |
JP2007511529A (ja) | 2007-05-10 |
US20110165177A1 (en) | 2011-07-07 |
US9850305B2 (en) | 2017-12-26 |
WO2005048935A3 (en) | 2006-03-30 |
EP1687066B1 (en) | 2012-08-29 |
AU2004291107B2 (en) | 2010-09-30 |
EP2397189A1 (en) | 2011-12-21 |
AU2004291107A1 (en) | 2005-06-02 |
CA2545806C (en) | 2014-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1098085A1 (en) | Methods of modulating immunity | |
GB0325192D0 (en) | Method of use | |
EP1745573A4 (en) | PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES | |
GB0326439D0 (en) | Methods | |
EP1685147A4 (en) | MODULATION OF EXPRESSION OF SGLT2 | |
GB2407131B (en) | Modulator | |
AU157323S (en) | Set of bottles | |
GB0306575D0 (en) | Modulators | |
GB0328243D0 (en) | Methods | |
EP1592431A4 (en) | METHOD FOR MODULATING IL-6 | |
AU2003295790A8 (en) | Modulation of iap-like expression | |
GB0326055D0 (en) | Signalling method | |
GB0327909D0 (en) | Methods | |
GB2401551B (en) | Stimulation aid | |
GB0327368D0 (en) | Methods | |
GB0320627D0 (en) | Methods | |
GB0327955D0 (en) | Teaching aid | |
AU2003264722A8 (en) | Methods | |
GB0204967D0 (en) | Methods | |
IL175170A0 (en) | Method of modulating hematopoiesis | |
GB0315827D0 (en) | Methods | |
GB0202213D0 (en) | Methods | |
GB0323793D0 (en) | Methods | |
GB0328747D0 (en) | Methods | |
GB0307076D0 (en) | Methods |